Question 1

What is Kalios Peptides?

Accepted Answer

Kalios is an independent reference database for peptide compounds. Every profile covers mechanism of action, clinical evidence, FDA status, and the honest limitations most sources skip. The site covers 113 peptide compounds and 6 stacks, plus a dosing/reconstitution calculator, the Stack Research Tool with 322 pre-generated pair pages, and an FDA PCAC 2026 review tracker. No paywall, no sales, no partner clinics.

Question 2

Is Kalios independent and free?

Accepted Answer

Yes. Kalios takes no money from compounding pharmacies, peptide vendors, sponsors, or affiliate programs. There is no paywall and no email gate. The site is supported solely by its independent author. Its position on every compound — including the PCAC 2026 review compounds — is neutral and based on published primary sources.

Question 3

How many peptide compounds does Kalios cover?

Accepted Answer

113 peptide compounds with full profiles, plus 6 stacks (Wolverine, KLOW, Glow, GH, Mito, Flow State) and the Stack Research Tool, which generates pair-compatibility pages for any two of the 113 compounds (322 pre-generated pair pages). Every profile follows a fixed 17-section template covering quick facts, mechanism, evidence, human data, dosing, reconstitution, side effects, monitoring, stacking, regulatory status, and 15+ verified primary references.

Question 4

What is the FDA PCAC 2026 peptide review?

Accepted Answer

On April 15, 2026 the FDA announced a two-day Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 to review seven peptides for inclusion on the Section 503A Bulk Drug Substances List. A second meeting before the end of February 2027 will review five more. Total: 12 peptides under PCAC review — BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, dihexa acetate, and PEG-MGF. Public comment deadline for the July meeting is July 9, 2026; docket FDA-2025-N-6895.

Peptides for regular people.